Investigating genetic factors in different types of glaucoma
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma
This study is trying to find out if certain genes are linked to different types of glaucoma by looking at blood samples from patients with these conditions and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 21 Years to 105 Years |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT03423758 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify genetic risk factors associated with pseudoexfoliation syndrome (PXF), primary angle closure glaucoma (PACG), and primary open-angle glaucoma (POAG) using a whole genome association approach. By analyzing blood samples from patients with these conditions and healthy controls, the study seeks to uncover susceptibility genes that may play a role in the development of glaucoma. The findings could enhance understanding of ocular development and lead to improved diagnostic and prognostic tools for these glaucoma types.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 21 and older with confirmed diagnoses of PXF, PACG, or POAG, as well as healthy controls over 60 years old.
Not a fit: Patients without any form of glaucoma or significant ocular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tests and treatment strategies for glaucoma patients.
How similar studies have performed: Previous studies have shown promise in identifying genetic factors related to glaucoma, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. For patients with PXF: * Patients with confirmed pseudoexfoliation syndrome (exfoliation glaucoma / pseudoexfoliation of the lens) in the medical history * Informed consent * Age 50 years or more 2. For patients with PACG: * Patients with confirmed acute primary angle closure (PAC) or primary angle closure glaucoma (PACG) in the medical history * Informed consent * Age 21 years or more 3. For healthy controls: * No evidence of PXF, glaucoma or uveitis during clinical examination or in the medical history * No evidence of major ocular disease such as diabetic retinopathy, age related macular degeneration or conditions with genetic background during clinical examination or in the medical history * Age more than 60 years * Informed consent 4. For patients with POAG: * Patients with confirmed primary open angle glaucoma (POAG) * No evidence of exfoliation glaucoma / pseudoexfoliation of the lens or pigment glaucoma * Informed consent * Age 30 or more Exclusion Criteria: * Patients and subjects will be excluded if one or more of the following criteria apply: * Neovascular glaucoma * Active or history of uveitis * Secondary angle closure such as neovascular glaucoma or uveitis/inflammatory eye disease * Inability to give informed consent
Where this trial is running
Vienna
- Department of Clinical Pharmacology, Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Principal investigator: Gerhard Garhöfer — Medical University of Vienna
- Study coordinator: Gerhard Garhöfer
- Email: gerhard.garhoefer@meduniwien.ac.at
- Phone: 0140 400 29880
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.